Oryzon Genomics S.A. (0RDB.L)

EUR 1.6

(-4.88%)

Total Debt Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual total debt in 2023 was 20.08 Million USD , down -16.04% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly total debt in 2024 Q2 was 19.26 Million USD , down 0.0% from previous quarter.
  • Oryzon Genomics S.A. reported annual total debt of 24.02 Million USD in 2022, up 20.5% from previous year.
  • Oryzon Genomics S.A. reported annual total debt of 19.94 Million USD in 2021, up 20.61% from previous year.
  • Oryzon Genomics S.A. reported quarterly total debt of 21.28 Million USD for 2023 Q2, down 0.0% from previous quarter.
  • Oryzon Genomics S.A. reported quarterly total debt of 20.08 Million USD for 2023 Q4, down 0.0% from previous quarter.

Annual Total Debt Chart of Oryzon Genomics S.A. (2023 - 2012)

Historical Annual Total Debt of Oryzon Genomics S.A. (2023 - 2012)

Year Total Debt Total Debt Growth
2023 20.08 Million USD -16.04%
2022 24.02 Million USD 20.5%
2021 19.94 Million USD 20.61%
2020 16.53 Million USD 11.28%
2019 14.85 Million USD -28.85%
2018 20.88 Million USD -25.61%
2017 28.06 Million USD 14.95%
2016 24.41 Million USD 147.83%
2015 9.85 Million USD -10.45%
2014 11 Million USD -28.78%
2013 15.44 Million USD 0.0%
2012 - USD 0.0%

Peer Total Debt Comparison of Oryzon Genomics S.A.

Name Total Debt Total Debt Difference
Boiron SA 13.7 Million EUR -46.603%
Laboratorios Farmaceuticos Rovi, S.A. 46.63 Million EUR 56.926%
Vetoquinol SA 17.62 Million EUR -13.953%
Valneva SE 208.81 Million EUR 90.38%
AB Science S.A. 19.1 Million EUR -5.165%
Nanobiotix S.A. 45.48 Million EUR 55.835%
PHAXIAM Therapeutics S.A. 10.19 Million EUR -96.956%
Vivoryon Therapeutics N.V. 38 Thousand EUR -52762.029%
BioSenic S.A. 28.16 Million EUR 28.669%
ABIVAX Société Anonyme 55.46 Million EUR 63.783%
Formycon AG 29.48 Million EUR 31.874%